Drug-delivery endovascular stent and method for treating restenosis
AssigneeBiosensors International Group, Ltd.
InventorsJohn E. Shulze, Ronald E. Betts, Douglas R. Savage
Life of this patent
Estimating the term…
Loading patent…
AssigneeBiosensors International Group, Ltd.
InventorsJohn E. Shulze, Ronald E. Betts, Douglas R. Savage
Estimating the term…
An intravascular stent and method for inhibiting restenosis, following vascular injury, is disclosed. The stent has an expandable, linked-filament body and a drug-release coating formed on the stent-body filaments, for contacting the vessel injury site when the stent is placed in-situ in an expanded condition. The coating releases, for a period of at least 4 weeks, a restenosis-inhibiting amount of the macrocyclic triene immunosuppressive compound everolimus. The stent, when used to treat a vascular injury, gives good protection against clinical restenosis, even when the extent of vascular injury involves vessel overstretching by more than 30% diameter. Also disclosed is a stent having a drug-release coating composed of (i) 10 and 60 weight percent poly-dl-lactide polymer substrate and (ii) 40–90 weight percent of an anti-restenosis compound, and a polymer undercoat having a thickness of between 1–5 microns.
A method for inhibiting restenosis at a vascular injury site, comprising
The method of 3, wherein said polymer undercoat is formed of a polymer selected from the group consisting of ethylene vinyl alcohol, parylast, silicone, a fluoropolymer, and parylene.
An endovascular stent for placement at a vascular injury site, for inhibiting restenosis at the site, comprising
Dependencies are inferred from the claim text.